Presentation of safety data from KeyzilenTM program and symposium on tinnitus pharmacotherapy set for September 18 and 19
ZUG, Switzerland, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that safety data from the KeyzilenTM (AM-101) program will be presented at the 2016 Annual Meeting & OTO EXPOSM of the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF). In addition, the company will host a corporate symposium featuring experts in the field of tinnitus research.[1]
Hinrich Staecker, MD, PhD, Professor of Otolaryngology at the University of Kansas Medical Center, will deliver an oral presentation titled “Safety of Repeated Intratympanic AM-101 in Acute Inner Ear Tinnitus” on September 18, 2016, at 11:40 am PDT at the San Diego Convention Center in Room 31A.
On September 19, 2016, at 6 pm PDT, Auris Medical will host a corporate symposium titled “Advancing Pharmacotherapy for Tinnitus.” The event will include presentations by Marlies Knipper, PhD, on the development of peripheral and central tinnitus; Lawrence R. Lustig, MD, on the history of intratympanic drug therapy; James A. Henry, PhD, on the clinical use of the Tinnitus Functional Index; and Hinrich Staecker, MD, PhD, on the clinical development of the NMDA receptor antagonist AM-101. The symposium will take place at the Hilton Bayfront Hotel in San Diego, and a webcast will be available in the Investor Relations section of the Auris Medical website at www.aurismedical.com following the event.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the Phase 3 development of treatments for acute inner ear tinnitus (KeyzilenTM; AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol “EARS.”
[1] This event is not part of the official AAO-HNSF 2016 Annual Meeting & OTO EXPOSM.
